2012
DOI: 10.2147/jaa.s34579
View full text
|
|
Share

Abstract: BackgroundCurrent therapy for allergic bronchopulmonary aspergillosis (ABPA) uses oral corticosteroids, exposing patients to the adverse effects of these agents. There are reports of the steroid-sparing effect of anti-IgE therapy with omalizumab for ABPA in patients with cystic fibrosis (CF), but there is little information on its efficacy against ABPA in patients with bronchial asthma without CF.ObjectiveTo examine the effects of omalizumab, measured by asthma control, blood eosinophilia, total serum immunogl…

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
47
0

Publication Types

Select...

Relationship

0
0

Authors

Journals